FDA局长马蒂·马卡里辞职
Read, Watch or Listen
Washington: Dr. Marty Makary resigned Tuesday as commissioner of the U.S. Food and Drug Administration, just over a year after taking the post. The resignation came after backlash from health industry executives, anti-abortion activists and other allies of President Donald Trump. Officials have not given an official reason for his departure; a White House official told FOX News the move related to "process at the FDA" and said there was "no bad blood" between Makary and the president. Kyle Diamantis, the FDA's deputy commissioner for Food, will serve as acting commissioner, according to FOX. Makary's tenure lasted just over a year; his resignation ends his leadership role and places Diamantis in the acting post while the agency proceeds under interim leadership.
Prepared by Lauren Mitchell and reviewed by editorial team.
Timeline of Events
- 2025年3月：参议院确认Marty Makary担任FDA局长。
- 2025–2026年初：该机构经历大规模裁员、领导层变动和政策争议。
- 2026年5月初：有报道称白宫批准了罢免Makary的计划。
- 2026年5月星期二：Makary辞去FDA局长职务；多家媒体报道了此消息。
- 随后：Kyle Diamantis (Diamantas) 被任命为FDA代理局长。
Why This Matters to You
美国食品药品监督管理局（FDA）负责监督食品和药品安全，直接影响您的健康。领导层的变动会改变优先事项和政策。请密切关注代理局长迪亚曼蒂斯（Diamantis）的任何新决定。
The Bottom Line
马卡里辞职标志着美国食品药品监督管理局 (FDA) 动荡一年结束。在迪亚曼蒂斯的领导下，该机构将迈向未来，他的行动将塑造其未来的发展方向。如果您认识健康行业的人，值得转发。
- Articles Published:
- 7
- Right Leaning:
- 1
- Left Leaning:
- 0
- Neutral:
- 6
- Distribution:
- Left 0%, Center 86%, Right 14%
某些政治盟友和倡导团体（包括生命组织和推动监管变革的行业利益相关者）批评马克里，在他辞职后，可能会暂时重新获得影响FDA优先事项制定的影响力。
患者、医疗服务提供者、FDA 工作人员以及行业利益相关者，在马卡里离职后，在监管决策方面面临短期不确定性，药物和器械审批可能出现延误。
Coverage of Story:
From Left
No left-leaning sources found for this story.
Comments